Cambridge Epigenetix, a UK-based company specializing in the development and application of epigenetic technologies, has announced the formation of its scientific advisory board (SAB) comprizing of experts in oncology, liquid biopsy and aging.
The board members' research perspectives are seen as key to the company, which spun-out of the University of Cambridge in 2012, transitioning towards becoming an integrated commercial epigenetic biomarker discovery venture.
"Their expertise will further help us to unlock the tremendous potential of epigenetic analysis and biomarker discovery"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze